15236
N,O-双(三甲基硅基)氨基甲酸酯
≥98.0% (T)
别名:
BSC, 三甲基硅烷基 N-三甲基硅烷基氨基甲酸酯
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
(CH3)3SiNHCO2Si(CH3)3
化学文摘社编号:
分子量:
205.40
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
252-520-4
Beilstein/REAXYS Number:
2043399
MDL number:
Assay:
≥98.0% (T)
Form:
solid
InChI key
DGIJAZGPLFOQJE-UHFFFAOYSA-N
InChI
1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)
SMILES string
C[Si](C)(C)NC(=O)O[Si](C)(C)C
assay
≥98.0% (T)
form
solid
mp
77-83 °C
functional group
amine
Quality Level
Other Notes
非常适于使醇、酚和羧酸甲硅烷基化的试剂。副产物仅为 CO2 和 NH3；可用于胺的甲硅氧基羰基化反应；以及由羧酰氯合成酰基异氰酸酯
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Zhur. Obshch. Khim., 50, 955-955 (1980)
Abi Vijenthira et al.
Blood, 136(25), 2881-2892 (2020-10-29)
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We
Barbara Melosky et al.
The oncologist, 25(1), 64-77 (2019-05-30)
Lung cancer is one of the most common types of cancer, resulting in approximately 1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become standard of care in advanced non-small cell lung cancer (NSCLC), and there is increasing interest in
V.P. Kozyukov et al.
Zhur. Obshch. Khim., 51, 239-239 (1981)
V.P. Kozyukov et al.
Current Chemical Reactions, 2, 6251-6251 (1980)
商品
Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持